



DEPARTMENT OF HEALTH & HUMAN SERVICES

Office of the Secretary  
Office of Public Health and Science

Office for Human Research Protections  
The Tower Building  
1101 Wootton Parkway, Suite 200  
Rockville, Maryland 20852

Telephone: 240-453-8132  
FAX: 240-453-6909  
E-mail: Kristina.Borrer@hhs.gov

September 2, 2010

Mary Simmerling, Ph.D.  
Director, Responsible Conduct of Research  
Weill Cornell Medical College  
445 E. 69th Street  
Olin 210  
New York, NY 10021

Jeff Silverstein, MD  
Associate Dean for Research  
Mount Sinai School of Medicine  
1 Gustave L Levy Place Box 1075  
New York, NY 10029

**RE:** Research Project: Steroid 21-Hydroxylase Deficiency  
Research Project: Hypo- and Hyperadrenal States  
Research Project: Low Renin Hypertension  
Research Project: Long Term Outcome in Offspring and Mothers of Dexamethasone-Treated Pregnancies at Risk for Classical Congenital Adrenal Hyperplasia Owing to 21-Hydroxylase Deficiency

Principal Investigator: Maria New, M.D.

Dear Drs. Simmerling and Silverstein:

This letter is in response to your reports to the Office for Human Research Protections (OHRP) regarding use of dexamethasone in pregnant women at risk of carrying a female fetus with congenital adrenal hyperplasia (CAH). OHRP has received your most recent letters of July 29, 2010 and August 2, 2010, concerning the above protocols. This correspondence relates to allegations OHRP received concerning activities conducted by Dr. Maria New at Weill Cornell Medical College (WCMC) and Mount Sinai School of Medicine (MSSM). Your reports and the actions described appear to be appropriate under HHS regulations and your institutions' Assurances of Compliance.

As you know, in evaluating this matter, OHRP first received reports from your institutions. We then sent you each several requests for additional information, which we reviewed thoroughly, including the research protocols and informed consent documents, and publications resulting from the research. We also had numerous discussions with staff at the U.S. Food and Drug Administration (FDA). As a result of

our review, we determine that the allegations raised by the complainants are unproven and we find no evidence that Dr. New violated the Department of Health and Human Services (HHS) regulations for the protection of human research subjects (45 CFR Part 46) involving the above-referenced research.

In specific, OHRP notes the following:

- (1) Dr. New conducted 3 studies while employed at WCMC involving provision of dexamethasone to pregnant women at risk of carrying a female fetus with CAH. The studies were reviewed and approved by the WCMC Institutional Review Board (IRB). Written informed consent (which included disclosure of risks) was obtained from subjects for participation in these studies. We find nothing inappropriate in either the IRB approval or conduct of these studies. From the information we reviewed, there appears to be no evidence that Dr. New engaged in clinical use of dexamethasone outside of research while at WCMC.
- (2) Since her arrival at MSSM in 2004, Dr. New has conducted one study that enrolled human subjects related to the use of dexamethasone in pregnant women at risk of carrying a female fetus with CAH. This project, which was initially reviewed by a MSSM IRB in 2004, involved cognitive testing and outcomes follow-up of patients who either had or had not been treated with dexamethasone during the prenatal period. According to the protocol, the decision as to whether a pregnant woman was treated or was not treated was not part of the study. We find nothing justifying a conclusion that the actions of the clinicians in treating those women should have been considered part of a clinical trial and subjected to IRB review. Dr. New was not the physician at MSSM for any of the cases included in her study. During Dr. New's tenure at MSSM, she prescribed dexamethasone for only one pregnant woman who had already been diagnosed with CAH. In this case, the treatment was not designed to prevent ambiguous genitalia in the fetus, but to continue needed treatment for the CAH-affected mother.

We are attaching a memo from the FDA summarizing their evaluation of the matter.

OHRP appreciates your continued commitment to the protection of human research subjects. Please do not hesitate to contact me should you have any questions.

Sincerely,

Kristina C. Borrer, Ph.D.  
Director, Division of Compliance Oversight



Office of Pediatric Therapeutics  
Office of the Commissioner  
10903 New Hampshire Ave., WO32-5216  
Silver Spring, MD 20993-0002  
Tel (301) 796-8665; FAX (301) 847-8619

MEMORANDUM

Date: August 30, 2010

From: Robert M. Nelson, M.D., Ph.D.  
Pediatric Ethicist and Lead Medical Officer  
Office of Pediatric Therapeutics, Office of the Commissioner, FDA

Through: Dianne Murphy, M.D., Director  
Office of Pediatric Therapeutics, Office of the Commissioner, FDA

To: Kristina C. Borrer, Ph.D.  
Director, Division of Compliance Oversight  
Office for Human Research Protections, DHHS

Re: Allegations concerning research activities conducted by Dr. Maria New at Weill Cornell Medical College (WCMC) and Mount Sinai School of Medicine (MSSM)

On February 3, 2010, a "Letter of Concern from Bioethicists" was sent to report suspected regulatory and ethics violations by Dr. Maria New in the use of dexamethasone during pregnancy for the purpose of preventing genital virilization associated with congenital adrenal hyperplasia in females. Copies of this letter were submitted to the FDA Office of Pediatric Therapeutics, the Office for Human Research Protections, and universities where Dr. New has held or holds appointments.

Dexamethasone treatment must be initiated in the 6th to 7th week of gestation, before sexual differentiation of genitalia occurs. Treatment is discontinued once the fetus is identified as being unaffected or male by chorionic villus sampling, usually performed at 10-12 weeks of gestation. If the fetus is female and affected (i.e., "at risk"), dexamethasone is continued until birth. For this indication, dexamethasone is administered at a very low dose of 20 micrograms/kg/day of pregnancy weight in 3 divided doses.

The submitted letter contained the following allegations:

1. Research on the use of dexamethasone for the prevention of virilization in "at risk" fetuses was conducted by Dr. New without appropriate IRB oversight.
2. Dr. New has publicly promoted dexamethasone as safe and effective for this use, when dexamethasone has not been approved for this indication by the FDA.

In addition to the above allegations, the letter outlined three major concerns about the risk/benefit profile of administering dexamethasone:

3. Prenatal dexamethasone treatment results in detrimental changes to the brains of children who are exposed, including problems with working memory, verbal processing, and anxiety;

4. Animal studies have also indicated reason to be concerned about prenatal dexamethasone's effect on fetal brains;
5. Genital virilization is only a cosmetic issue for which alternative postnatal treatments exist.

Review Process:

In response to the Letter of Concern, the Office of Pediatric Therapeutics (OPT) spoke with representatives from a number of offices within the Center for Drug Evaluation and Research, including the Division of Scientific Investigation, the Pediatric and Maternal Health Staff and the Division of Reproductive and Urologic Products in the Office of New Drugs, and the Division of Drug Marketing, Advertising, and Communications. In addition, the HHS Office for Human Research Protections (OHRP) requested investigations by the universities identified by the Letter of Concern. The results of these investigations have been reviewed by OPT, and discussed with OHRP. The findings of this investigation are summarized below.

Summary Findings:

The available evidence indicates that:

1. Dr. New's research was (specifically, three studies at WCMC between 1985 and 2004) and continues to be conducted (specifically, one study at MSSM) under appropriate IRB oversight, based on the available documentation.
2. Existing data are insufficient to draw conclusions regarding the risk/benefit claims made in the Letter of Concern. Dexamethasone appears to reduce virilization of affected females without causing fetal malformations. High-dose dexamethasone has known adverse effects on growth and development in animals, but similar effects at low doses have not been proven. Further prospective studies are required to determine whether prenatal treatment with dexamethasone should be routinely recommended. We discuss this issue in more depth below.
3. Dr. New received an IND exemption from FDA in 1996 under 21 CFR 312.2(b) for the administration of dexamethasone during pregnancy for the purpose of preventing virilization in females with congenital adrenal hyperplasia.
4. The current administration of dexamethasone to pregnant women in order to prevent genital virilization in "at risk" females does not constitute a "clinical investigation" as the drug is being prescribed based on the clinical judgment of the women's personal physicians who are then referring the women for follow-up in Dr. New's IRB-approved research protocol.
5. The use of dexamethasone for the prevention of genital virilization in "at risk" females has not been approved by the FDA. Dexamethasone is thus being used for this "off label" as part of the clinical practice of medicine. Dexamethasone has not been found to be safe and effective for this indication by FDA.
6. FDA regulations that prohibit the promotion of "off label" use of medications apply to a sponsor, and not to physicians using the medication as part of the practice of medicine.

Discussion of the Safety of using Dexamethasone during Pregnancy:

We now summarize our assessment of the safety issues posed by this treatment in children. One study assessed the frequency and etiology of white-matter changes and temporal lobe atrophy demonstrable on MRI in a group of children and young adults with congenital adrenal hyperplasia (Nass, 1997). The authors noted that exposure to excess glucocorticoids in the process of treatment for congenital adrenal hyperplasia was a theoretically appealing explanation for these MRI findings. However, there is no clear dose-response relationship between the glucocorticoids and the MRI findings, and no correlation between MRI findings and neurological examinations.

Data on memory and processing in children who were treated prenatally with dexamethasone for CAH are small, conflicting, and difficult to interpret. Different methods of assessment were used with children at different age groups, and some studies have focused on parental perception rather than student performance. In general, no differences were observed between dexamethasone-treated children and controls in parental ratings of cognitive or motor development or school performance (Meyer-Bahlburg, 2004). Although an increase in social anxiety was observed in the CAH-unaffected dexamethasone-treated group when children rated themselves, parental ratings did not concur. Visuospatial working memory was mildly poorer in the dexamethasone-treated group, but the difference was not statistically significant (Hirvikoski, 2007). Dexamethasone-treated individuals also had poorer verbal working memory and perception of school performance than controls (Hirvikoski, 2007). However, the authors were later unable to reproduce these findings, and on further analysis concluded that they were due to a small sample size (Hirvikoski, 2008).

A number of studies of dexamethasone administration have been conducted in animals, including rats, rabbits, and primates. While adverse effects ranging from impaired memory to an exaggerated cortisol response to mild stress have been found, the animal models have been designed to imitate either the treatment of premature infants or have used very high doses of dexamethasone (Lajic, 2008). The NOAEL has not been determined, and there are few animal data using lower doses of dexamethasone that would be consistent with the prenatal indication in CAH. One study in fetal sheep suggested that early exogenous dexamethasone directly increases fetal adrenal activation but not anterior pituitary function (Braun, 2009).

Girls with CAH in its more severe forms present with a persistent urogenital sinus, in which the urethra and vagina fail to separate into separate channels. Surgical reconstruction to separate the urinary and reproductive tracts in childhood is necessary to prevent urinary incontinence and infections leading to renal damage as well as to allow normal urination and future sexual function (Diamond et al. 2010). Even uncomplicated clitoromegaly may require surgery to correct, which poses medical risks to the child.

The observational nature and small sample size of the whole body of literature pertaining to dexamethasone in this setting significantly weaken inferences about the benefits and harms of treatment. Dexamethasone seems to be associated with reduction in virilization of affected females without significant maternal or fetal adverse effects (Fernández-Balsells, 2010). There are no data on long term follow-up of physical and metabolic outcomes in children exposed to

dexamethasone. High-dose dexamethasone has known adverse effects on growth and development in animals, but similar effects at low doses have not been proven. Further prospective studies are required to determine whether prenatal treatment with dexamethasone should be routinely recommended.

#### References

1. Braun T, Li S, Sloboda DM, Li W, Audette MC, Moss TJ, Matthews SG, Polglase G, Nitsos I, Newnham JP, Challis JR. Effects of maternal dexamethasone treatment in early pregnancy on pituitary-adrenal axis in fetal sheep. *Endocrinology*. 2009 Dec;150(12):5466-77.
2. Diamond, D, Ecker J, Holm I, Kornetsky S, Mitchell C, Spack N. 2010 Not fetal cosmetology. The Hastings Center Bioethics Forum, March 8, 2010. Available at <http://www.thehastingscenter.org/Bioethicsforum/Post.aspx?id=4528&blogid=140>, Accessed August 16, 2010.
3. Fernández-Balsells MM, Muthusamy K, Smushkin G, Lampropoulos JF, Elamin MB, Abu Elnour NO, Elamin KB, Agrwal N, Gallegos-Orozco JF, Lane MA, Erwin PJ, Montori VM, Murad MH. Prenatal Dexamethasone Use For The Prevention Of Virilization In Pregnancies At Risk For Classical Congenital Adrenal Hyperplasia due to 21 hydroxylase (CYP21A2) deficiency: A Systematic Review And Meta-Analyses. *Clin Endocrinol (Oxf)*. 2010 Jun 9.
4. Hirvikoski T, Nordenström A, Lindholm T, Lindblad F, Ritzén EM, Wedell A, Lajic S. Cognitive functions in children at risk for congenital adrenal hyperplasia treated prenatally with dexamethasone. *J Clin Endocrinol Metab*. 2007 Feb;92(2):542-8.
5. Hirvikoski, T., A. Nordenström, T. Lindholm, F. Lindblad, E.M. Ritzén, and S. Lajic. 2008. Long-term follow-up of prenatally treated children at risk for congenital adrenal hyperplasia: does dexamethasone cause behavioural problems? *European Journal of Endocrinology* 159 309–316.
6. Lajic S, Nordenström A, Hirvikoski T. Long-term outcome of prenatal treatment of congenital adrenal hyperplasia. *Endocr Dev*. 2008;13:82-98.
7. Meyer-Bahlburg HF, Dolezal C, Baker SW, Carlson AD, Obeid JS, New MI. Cognitive and motor development of children with and without congenital adrenal hyperplasia after early-prenatal dexamethasone. *J Clin Endocrinol Metab*. 2004 Feb;89(2):610-4.
8. Nass R, Heier L, Moshang T, Oberfield S, George A, New MI, Speiser PW. Magnetic resonance imaging in the congenital adrenal hyperplasia population: increased frequency of white-matter abnormalities and temporal lobe atrophy. *J Child Neurol*. 1997 Apr;12(3):181-6.